ARTICLE | Emerging Company Profile
Octant: leveraging cell barcoding for small molecule design
Bay Area biotech unveils $80M B round, BMS deal while adding Rick Artis as CSO, Feng Zhang to SAB
April 23, 2022 12:52 AM UTC
Octant’s latest funding round and hires sees the synthetic biology and chemistry platform company shifting its focus to therapeutic programs.
“We’ve moved from just pure technology to now trying to build real drugs,” said co-founder and CEO Sri Kosuri...